Immunitybio News
News
0
Ticker
IBRX
ISIN
US45256X1037
Immunitybio Eulerpool News
Immunitybio Stock News
Immunitybio is being monitored by journalists and investors worldwide. We gather the latest Immunitybio news here.
- October 19·SeekingAlpha
- October 16·SeekingAlpha
- October 15·Benzinga
- October 15·Benzinga
- October 15·Yahoo
- October 9·Benzinga
- October 8·Yahoo
- October 8·Yahoo
- October 5·Yahoo
- October 2·Yahoo
- October 1·Yahoo
- September 30·Yahoo
- September 30·Yahoo
- September 23·Yahoo
- September 21·Yahoo
- September 18·Yahoo
- September 16·Yahoo
- September 15·Yahoo
- September 14·Yahoo
- September 11·Yahoo
Immunitybio Stock Press Releases
Immunitybio regularly publishes news on the company's website that are relevant for investors.
- November 17•Immunitybio
- November 10•Immunitybio
- October 27•Immunitybio
- July 28•Immunitybio
- June 6•Immunitybio
- May 23•Immunitybio
- April 28•Immunitybio
- April 25•Immunitybio
- April 1•Immunitybio
- March 2•Immunitybio
- February 14•Immunitybio
- January 31•Immunitybio
- January 18•Immunitybio
- January 4•Immunitybio
- January 3•Immunitybio
- December 21•Immunitybio
- December 20•Immunitybio
- November 18•Immunitybio
- November 8•Immunitybio
- November 4•Immunitybio
- October 19•Immunitybio
- October 13•Immunitybio
- October 4•Immunitybio
- September 13•Immunitybio
- September 7•Immunitybio
- September 1•Immunitybio
- August 16•Immunitybio
- July 29•Immunitybio
- July 27•Immunitybio
- July 14•Immunitybio
Immunitybio News 2026
This page contains all current news, analysis and press releases for Immunitybio stock (IBRX, ISIN: US45256X1037). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Immunitybio.
Immunitybio Stock
Immunitybio Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide.